

1 **Title: Association of Lung Fibrotic Changes and Cardiological Dysfunction with**
2 **Hypertension in Long COVID-19 cohort**

3 Authors

4 Ainur Tauekelova¹, Zhanar Kalila¹, Bakhtiyar Akerke¹, Zarina Sautbayeva², Polina Len²,
5 Aliya Sailybayeva¹, Sadyk Khamitov¹, Nazira Kadroldinova³, Natalie S. Barteneva^{*2,4} and
6 Makhabbat Bekbossynova^{*1}

7
8 Affiliations

9 ¹National Research Center for Cardiac Surgery, Nur-Sultan, Kazakhstan

10 ²School of Sciences and Humanities, Nazarbayev University, Nur-Sultan, Kazakhstan

11 ³School of Medicine, Nazarbayev University, Nur-Sultan

12 ⁴Harvard Medical School, Brigham and Women's Hospital, Boston, MA, United States

13 *Corresponding author

14
15 Keywords: LongCOVID-19; post-COVID-19; hypertension; diabetes; ferritin; fibrinogen; lung
16 sequelae; cardiovascular sequelae; female gender

17
18 **Abstract**

19 **Background.** Long COVID-19 symptoms appeared in many COVID-19 survivors. However, the
20 prevalence and symptoms associated with long COVID and its comorbidities have not been
21 established.

22 **Methods.** Between May and September 2020, we included 312 patients with post-COVID-19
23 from 21 primary care centers if they had any persistent symptoms for at least three months from
24 the first onset of the disease. On the 6 months follow up, their lung function was assessed by CT
25 and spirometry, whereas cardiac function was assessed by electrocardiogram (ECG), Holter
26 ECG, Echocardiography, and 24-hour blood pressure monitoring. A six-minute test (6MWT)
27 was conducted on 308 participants during the follow-up visit. All participants were given a
28 questionnaire with items on demographic information, current complaints, comorbidities, and
29 medications, and Chalder Fatigue Scale (CFS) questionnaire. Statistical analysis was done using
30 R vs. 4.1.2. Two-group comparison of continuous variables was performed using a T-test for
31 normally distributed data, and the Mann-Whitney Wilcoxon test, ANOVA, and Kruskal-Wallis
32 tests were applied for multiple comparisons following with Tukey and Dunn tests as post-hoc
33 methods. Hochberg p-value adjustment was used to reduce the false discovery rate during
34 multiple comparisons. Categorical variables were analyzed with Fisher's Exact test.

35 **Results.** Of 312 persons investigated, there was no significant gender difference between post-
36 COVID-19 clinical manifestations except for memory dysfunction and anxiety, more prevalent
37 among female participants. Chalder Fatigue Score ≥ 4 was predominant in female participants
38 (243, 78%). 39 (12.5%) participants reported having type 2 diabetes mellitus, and 158 (50.64%)
39 had hypertension.

40 Among the tested parameters, those positively correlated with comorbid conditions include age,
41 BMI, D-dimers, NT-proBNP, C-reactive protein, neutrophils, fasting glucose, and HbA1c;
42 hypertension also shows three associations that were not found in patients when examining the
43 role of diabetes: increased hemoglobin, fibrinogen, and ferritin. 24-hour blood pressure
44 monitoring revealed significantly higher systolic and diastolic blood pressure, left ventricular
45 hypertrophy, and elevated NT-proBNP in participants with hypertension and subjects with type 2

46 diabetes. Left ventricular diastolic dysfunction is more frequently present in patients with
47 hypertension.

48 Chest CT was conducted on 227 (72.8%) participants 5.8±0.9 months after the onset of
49 COVID-19. The most common registered CT abnormality was chronic bronchitis (198, 87.2%),
50 followed by fibrotic changes in (83, 36.6%) and mediastinal lymphadenopathy (23, 10.1%).

51 Immunological test results showed that SARS-CoV19 IgG antibodies were present in 241
52 subjects (77.2%), and SARS-CoV19 IgM antibodies were present in 9 subjects (2.88%).

53 **Conclusions.** Our study provides valuable clues for long-term post-sequelae in a cohort of the
54 Long COVID-19 subjects. We demonstrated a strong association of signs of cardiac dysfunction,
55 lung fibrotic changes, increased hemoglobin, fibrinogen, and ferritin with hypertension but not
56 with other comorbidities. Our results are of importance for understanding the Long Covid-19
57 syndrome.

58

59 **Introduction**

60 The COVID-19 disease, resulting from infection with SARS-CoV-2, is highly contagious and
61 may spread asymptotically or presymptomatically (Furukawa et al., 2020; Rivett et al., 2020;
62 Buitrago-Garci et al., 2020). There is a growing concern regarding the potential for COVID-19
63 infection to contribute to a burden of chronic cardiovascular and respiratory symptoms among
64 recovered individuals (Leth et al., 2021). The SARS-CoV2 virus appears unique among
65 coronaviruses due to the high rate of transmission and atypical pattern of inflammatory response
66 leading in severe cases to cytokine storm phenomenon (rev. Tang et al., 2020). Long-COVID-19
67 or post-COVID-19 syndrome describes symptoms lasting for more than three months after the
68 first COVID-19 symptoms onset (Yong, 2021), and there is a critical need to evaluate and
69 understand potential long-term implications of COVID-19. The most frequent symptoms are
70 shortness of breath and fatigue (Cares-Marambio et al., 2021; Shah et al., 2021; Davido et al.,
71 2020; Halpin et al., 2020).

72 Many meta-analyses identified that the elderly population with pre-existing disease conditions
73 such as type 2 diabetes mellitus (Singh et al., 2020; Kumar et al., 2020) and hypertension
74 (Pranata et al., 2020; de Almeida-Pititto et al., 2021) are found to be at an increased risk of
75 getting COVID-19 infection and its complications (Deng et al., 2020). COVID-19 has been
76 linked to multiple extra-respiratory symptoms more prevalent in patients with positive
77 cardiovascular disease history (Han et al., 2020). Long-lasting alternations in pulmonary
78 function, including the reduced diffusing capacity of lungs and the restrictive syndrome, were
79 observed in patients surviving COVID-19 pneumonia during a 6-month and 12 months follow-up
80 period (Fortini et al., 2021; Fumagalli et al., 2021; Wu et al., 2021; Ordinola Navarro et al.,
81 2021). However, long COVID affects even mild-to-moderate cases of survivors of COVID-19
82 with pulmonary sequelae reported after recovery (Wang et al., 2020).


83 In this paper, we report results from a prospective cohort study of 312 patients with COVID-19
84 onset between May and September 2020. We are aimed to determine the prevalence and extent
85 of allowing analysis of persisting Long COVID-19 symptoms over 6 months duration
86 emphasizing the patient's cardiovascular and lung sequelae of COVID-19.

87

88 2. Materials and Methods

89 2.1 Study design and participants.

90 This is a prospective cohort study that was based on a pilot project of the post-COVID center
91 in JSC "National Research Cardiac Surgery Center" in Nur-Sultan, Kazakhstan. The study was
92 conducted in December 2020. The post-COVID center was established according to the order of
93 the Ministry of Health of the Republic of Kazakhstan No. 763 dated November 24, 2020, as a
94 pilot project for the improvement of the coronavirus infection situation in the healthcare of the
95 country. Participants were referred from the primary care centers of Nur-Sultan (Kazakhstan) to
96 the post-COVID center. Participants were selected if they had any persistent symptoms for at
97 least three months from the first onset of the disease. Selected 312 were referred to the follow-up
98 visit to JSC "National Research Cardiac Surgery Center." All participants had confirmed
99 infection with positive PCR during the active infection or laboratory immunohistochemical
100 results. The study was ethically approved according to the order of the Ministry of Health of the
101 Republic of Kazakhstan, and informed consent was taken in the primary care centers.



102

103 **Figure 1.** Study flow diagram.

104 2.2 Clinical Assessment

105 All participants were given a questionnaire with items on demographic information, current
106 complaints, comorbidities, and medications (**Appendix 1**). All participants were given Chalder
107 Fatigue Scale (CFS) questionnaire (**Appendix 2**) for completion. Vital signs of participants,
108 including blood pressure and heart rate were performed by one of three physicians participating
109 in data collection. Venous blood samples were collected from all participants for complete blood
110 count, including hemoglobin, white blood cells, lymphocytes, neutrophils, and platelet count, for
111 biochemistry panel, including serum creatinine, blood urea, total cholesterol, glucose, and ALT,
112 for coagulation profile, including fibrinogen and D-Dimer (DD), and for glycohemoglobin A_{1c}
113 (HbA_{1c}), C-reactive protein, ferritin, vitamin B12, vitamin 25(OH)D, and NT-proBNP. For
114 coagulation tests AVATUBE R with sodium citrate was used, and Sysmex CS-2500 instrument

115 (Sysmex, Japan). Blood for DD was collected in AVATUBE R with sodium citrate, and D-
116 dimers quantification was performed with Cobas R 6000. Additionally, blood analysis for
117 immunological tests was performed, including SARS-CoV-2 IgG, SARS-CoV-2 IgM, CMV
118 IgG, and CMV IgM antibodies quantified by ELISA. All participants were proposed chest CT,
119 but 85 participants (28.3%) refused due to personal claims. Cardiac function was assessed by
120 electrocardiogram (ECG), Holter ECG, Echocardiography, and 24-hour blood pressure
121 monitoring in all participants. A six-minute test (6MWT) was conducted in 308 participants at
122 the follow-up visit. The medical records of each participant were reviewed independently by
123 three physicians (cardiologist with more than 10 years of experience) of the hospital. All CT
124 images were reviewed in random order by one senior cardiothoracic radiologist who were not
125 aware of any clinical or laboratory findings or participant outcomes. The confirmation of
126 COVID-19 infection was done by RT-PCR assay on nose/throat swab or sputum samples using
127 CFX96 R Real-Time System (Bio-Rad Laboratories, Inc., USA).

128

129 **2.3 Statistical Analysis**

130 Statistical analysis was performed in parallel using R vs. 4.1.2 (2021-11-01) and GraphPad
131 Prism vs. 8.4.3 (Dotmatics, USA). Normality was assessed using the Shapiro test. Two-group
132 comparison of continuous variables was performed using T-test for normally distributed data and
133 MannWhitney Wilcoxon test if the condition of normality was violated. For multiple
134 comparisons ANOVA and Kruskal-Wallis tests were applied with Tukey and Dunn tests as post-
135 hoc methods. Hochberg p-value adjustment was used to reduce the false discovery rate during
136 multiple comparisons. Categorical variables were analyzed with Fisher's Exact test.

137

138 **2.4 Role of funding source**

139 This research has been funded by the Science Committee of the Ministry of Education and
140 Science of the Republic of Kazakhstan (Grant No. BR10965164). <https://www.ncste.kz/en/main>.
141 The funders had no role in study design, data collection and analysis, decision to publish, or
142 preparation of the manuscript.

143

144 **2.5 Ethical considerations**

145 All participants of the study provided written informed consent. The study was approved by the
146 National Research Center Cardiac Surgery Center Ethical Committee (#01-97/2021 from
147 22/04/21). No compensation was provided to participants (only reimbursing of travelling costs).

148 **3. Results**

149 **3.1 Cohort description**

150 The comorbidities are reported in **Table 1** from the most prevalent to the least. Overall, 223
151 participants had at least one comorbidity. The most common comorbidities included
152 hypertension (154, 50.6%), gastrointestinal (GI) disorders (74, 23.73%), and neurological
153 disorders (43, 13.78%). Some of the participants also had overlapping of the comorbidities.

154 The proportion of coronary artery disease (CAD) in male participants was higher than in
155 females, 14.85% in males vs. 7.11% in females, $P=0.030$. Meanwhile, endocrine disorders were
156 more prevalent among female participants (16, 7.58%) vs. 1, 0.99%), respectively, $P=0.016$.

157 Respiratory comorbidities include asthma and chronic obstructive disease (COPD) (9, 2.88%)
158 with no significant difference among female and male participants.

159
160
161

Table 1. Clinical characteristic and comorbidities in participants after COVID-19 infection.

	Total (n=312)	Female (n=211)	Male (n=101)	<i>P</i> -value
Age [†] , years	54 (42.5;60)	54 (44;60)	55 (40;61)	0.689
BMI [†] , kg/m ²	26.9 (23.4;31.1)	26.9 (23.1;31.6)	26.7 (24;30.4)	0.531
Obesity class				
Overweight (BMI 25.0–29.9)	90 (28.9)	57 (27.0)	33 (32.7)	0.302
Obese (BMI ≥30.0)	103 (33.0)	73 (34.6)	30 (29.7)	0.390
CFS ≥4	243 (77.9)	173 (82.0)	70 (69.31)	0.012
Hypertension	158 (50.6)	112 (53.1)	61 (60.4)	0.224
GI disorders	74 (23.7)	49 (23.2)	25 (24.7)	0.766
Neurological disorders	43 (13.8)	31 (14.7)	12 (11.9))	0.500
Type 2 Diabetes	40 (12.8)	27 (12.8)	12 (12.9)	0.985
CAD	30 (9.62)	15 (7.10)	15 (14.9)	0.030
Endocrine disorders	17 (5.45)	16 (7.58)	1 (0.99)	0.016
Heart Failure	14 (4.49)	8 (3.79)	6 (5.94)	0.391
UTI disorders	14 (4.49)	7 (3.32)	7 (6.93)	0.149
Rhythm disturbances	6 (1.92)	3 (1.42)	3 (1.42)	0.157
Asthma	7 (2.24)	6 (2.84)	1 (0.99)	0.301
COPD	2 (0.64)	1 (0.47)	1 (0.99)	0.593

Note. Except where indicated, data are numbers of participants, with percentages in parentheses. *P* values comparing female and male participants were determined with the Fisher’s Exact test, independent-samples *t* test, or Mann-Whitney *U* test.

CFS – Chalder Fatigue Score

GI disorders include chronic cholecystitis, pancreatitis, steatohepatitis, and atrophic gastritis

Neurological disorders include encephalopathy of mixed etiology;

endocrine disorders include hypothyroidism.

†Data are medians, with interquartile ranges in parentheses.

162

163 A total of 312 participants who were previously infected with COVID-19 infection were
 164 included in the study. Mean time for the post-COVID-19 assessment was 5.8 ± 0.9 months onset
 165 of first symptoms of COVID-19 infection. 111 participants had hospitalization during the active
 166 COVID-19 infection while 201 participants were treated at home. Clinical characteristics of the
 167 participants are reported in **Table 1**.

168 Median age of all participants were 54 years (IQR, 17.5) and 211 participants (67.6%) were
 169 females. One participant required extracorporeal oxygenation membrane oxygenation (ECMO)
 170 during the active infection. Median age of all participants was 54 years (IQR, 17.5) and 211
 171 participants (67.6%) were females. Median BMI of all participants was 26.9 kg/m^2 (IQR, 7.7)
 172 with 90 participants (28.9%) overweight and 103 participants (33.0%) obese. Chalder Fatigue
 173 Score ≥ 4 was present in 243 participants (78%) with more predominance in female participants.
 174

175 **3.2 Clinical manifestations at the follow-up and laboratory results**

176 Clinical manifestations of participants at the follow-up are reported in **Table 2**. The symptoms
 177 are presented from the most common to the least. The most common symptoms among 312
 178 participants were fatigue (220, 70.51%), tiredness (180, 57.69%), and sleep disturbances (168,
 179 53.85%), muscle pain (109, 34.9%), memory dysfunction (108, 34.9%), dizziness (34.9%),
 180 headache (79, 25.3%), instability of blood pressure mostly with increased systolic blood pressure
 181 (62, 19.9%), palpitation (47, 15.1%), dyspnea on exertion (45, 14.4%), joint pain (39, 12.5%),
 182 and increased sweating (39, 12.5). Overall, there were no significant difference between post-
 183 COVID-19 clinical manifestations among female and male participants, except memory
 184 dysfunction and anxiety. Both were more prevalent among female participants, 81 female
 185 participants (38.4%) reported memory dysfunction (27 male participants (26.7%), $P=0.043$) and
 186 28 female participants (12.3%) reported anxiety (2 male participants (1.98%), $P=0.003$).

187 **Table 2.** Participants-reported clinical manifestations persistent after COVID-19 infection at
 188 median of 6 months follow-up.

	Total (n=312)	Female (n=211)	Male (n=101)	<i>P</i> -value
Fatigue	220 (70.5)	143 (67.8)	77 (76.2)	0.125
Tiredness	180 (57.7)	118 (55.9)	62 (61.5)	0.361
sleep disturbances	168 (53.9)	116 (55.0)	52 (51.5)	0.563
Muscle pain	109 (34.9)	78 (37.0)	31 (30.7)	0.277

memory dysfunction	108 (34.6)	81 (38.4)	27 (26.7)	0.043
dizziness	107 (34.3)	80 (37.9)	27 (26.7)	0.052
headache	79 (25.3)	59 (28.0)	20 (19.8)	0.121
BP instability	62 (19.9)	38 (18.0)	24 (23.8)	0.233
Palpitation	47 (15.1)	34 (16.1)	13 (12.9)	0.454
Dyspnea on exertion	45 (14.4)	31 (14.7)	14 (13.9)	0.845
joint pain	39 (12.5)	30 (14.2)	9 (8.9)	0.185
increased sweating	39 (12.5)	29 (13.7)	10 (9.9)	0.337
anxiety	28 (8.97)	26 (12.32)	2 (1.98)	0.003
hair loss	27 (8.65)	19 (9.00)	8 (7.92)	0.750
Dyspnea on rest	18 (5.77)	11 (5.21)	7 (6.93)	0.543
decreased vision	18 (5.77)	12 (5.69)	6 (5.94)	0.928
GI symptoms	16 (5.13)	12 (5.69)	4 (3.96)	0.518
chest pain in rest	12 (3.85)	11 (5.21)	1 (0.99)	0.070
Daytime sleeping	11 (3.53)	6 (2.84)	5 (4.95)	0.563
Cough with sputum	9 (2.88)	7 (3.32)	2 (1.98)	0.509
mood change	8 (2.56)	5 (2.37)	3 (2.97)	0.753
chest pain on exertion	7 (2.24)	5 (2.37)	2 (1.98)	0.828
dry cough	7 (2.24)	7 (3.32)	0	0.064
numbness in extremity	7 (2.24)	5 (2.37)	2 (1.98)	0.828
decreased hearing	6 (1.92)	6 (2.84)	0	0.087
tremor in extremity	5 (1.60)	3 (1.42)	2 (1.98)	0.713
Impaired sense of smell	5 (1.60)	3 (1.42)	2 (1.98)	0.713
increased weight	4 (1.28)	3 (1.42)	1 (0.99)	0.751
decreased concentration	3 (0.96)	2 (0.95)	1 (0.99)	0.971
Wheezing	2 (0.67)	1 (0.47)	1 (0.99)	0.593

nervousness	2 (0.64)	2 (0.95)	0	0.326
presyncope	2 (0.64)	2 (0.95)	0	0.326
syncope	2 (0.64)	2 (0.95)	0	0.593
Impaired sense of taste	2 (0.64)	1 (0.47)	1 (0.99)	0.593
fever	2 (0.64)	1 (0.47)	1 (0.99)	0.593
edema of extremities	2 (0.64)	2 (0.95)	0	0.326
<p>Note.— Data are numbers of participants, with percentages in parentheses. <i>P</i> values comparing female and male participants were determined with the χ^2 test. BP – blood pressure</p>				


189

190 Out of 312 participants, 148 (47.44%) had neither hypertension nor type 2 diabetes mellitus, 33
 191 (10.58%) had both hypertension and diabetes, 125 (40.06%) had hypertension only, and 6
 192 (1.92%) participants had diabetes only. Overall, 39 (12.5%) participants reported having type 2
 193 diabetes mellitus, and 158 (50.64%) had hypertension. Among the tested parameters, those
 194 positively correlated with comorbid conditions include age, BMI, D-dimers, NT-proBNP, C-
 195 reactive protein, neutrophils, fasting glucose, and HbA1c; hypertension also shows three
 196 associations that were not found in patients when examining the role of diabetes: increased
 197 hemoglobin, fibrinogen, and ferritin (**Figures 2-4**).

198 Multiple group comparisons had shown that from the parameters highlighted above, older age,
 199 higher body mass index, increased D-dimers, and NT-proBNP are primarily correlated with
 200 hypertension rather than diabetes mellitus. On the other hand, higher levels of fasting glucose,
 201 HbA1c, and C-reactive protein are attributed to having both comorbid states rather than one.
 202 Neutrophils, white blood cells, NT-pro BNP, hemoglobin, and fibrinogen were not significantly
 203 different among groups, according to the post-hoc test.

204

205



206

207

208 **Figure 2.** Clinical characteristics and laboratory results of blood samples in post-COVID-19


209 patients with and without type 2 diabetes: age, D-dimers (DD), ventricular natriuretic peptide

210 (NT-proBNP), C-reactive protein (CRP), body mass index (BMI), neutrophils, fasting glucose

and glycated hemoglobin (HbA1c) (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$).


211

212



213
214

215 **Figure 3.** Clinical characteristics and laboratory results of blood samples in post-COVID-19
216 patients with and without hypertension: age, BMI, NT-proBNP, CRP, neutrophils, white blood
217 cells (WBC), DD, fasting glucose, HbA1c, HGB, fibrinogen and ferritin (* $p < 0.05$, ** $p < 0.01$,
218 **** $p < 0.0001$).




219
220
221
222
223
224
225
226
227

Figure 4. Clinical characteristics and laboratory results of blood samples in post-COVID-19 patients with no comorbidities (green), hypertension only (blue), type 2 diabetes mellitus only (orange) and both hypertension and type 2 diabetes (red): age, BMI, NT-proBNP, CRP, neutrophils, WBC, DD, fasting glucose, HbA1c, HGB, fibrinogen and ferritin (** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$).

3.3 Lung Function Screening

228 **Chest CT.** At the follow-up visit with mean of 5.8 ± 0.9 months chest CT was conducted in 227
 229 subjects (72.8%). All the chest CT findings are reported in **Table 4** from the most common to the
 230 least common findings. 12 subjects (5.29%) had normal chest CT. The most common registered
 231 CT abnormality was chronic bronchitis in (198, 87.2%) followed by fibrotic changes in (83,
 232 36.6%) and mediastinal lymphadenopathy in (23, 10.1%). Most of the participants had more than
 233 one CT changes. Median age of participants with lung abnormalities in chest CT was 55 years of
 234 age (IQR, 7). on 227 (72.8%) participants. Other CT abnormalities included polysegmental
 235 pneumonia, bronchiectasis, emphysema, bullous changes, atelectasis, and interstitial pneumonia
 236 (**Appendix 3**). These chest CT findings do not have a comorbidity-associate predisposition.
 237 However, fibrotic changes were found in 55 out of 158 patients with hypertension in comparison
 238 to 30 out of 154 participants without hypertension. (**Figure 5A**).

239 Overall, 107 participants had chest CT during active COVID-19 infection, with the mean
 240 percentage of lung defects $36.5 \pm 22.6\%$. Among those participants, 87 subjects (39.6%)
 241 underwent chest CT at the follow-up, and 84 (96.6%) subjects had residual lung abnormalities
 242 detected at the follow-up.



244 **Figure 5.** Fibrotic changes in CT scan of post-COVID-19 patients with hypertension (**A**).
 245 Cardiac abnormalities in post-COVID-19 patients with and without hypertension (**B**); with and
 246 without type 2 diabetes (**C**). (* $p < 0.05$, *** $p < 0.001$, **** $p < 0.0001$).
 247

248

249 **Spirometry test.** All participants had spirometry test at the follow-up visit and 143 subjects
250 (45.8%) had spirometry without abnormalities. From 169 subjects (54.2%) with abnormal
251 spirometry 118 subjects (37.8%) had restrictive pattern and 43 subjects (13.8%) had mixed
252 results with mostly restrictive pattern. Only 8 subjects (2.6%) had obstructive defects detected in
253 spirometry. Regarding participants with respiratory comorbidities (9), there were 1 participant
254 with restrictive, 1 participant with obstructive, and 4 participants with mixed with mostly
255 restrictive defects. 67 participants (60.3%) out of 111 hospitalized participants had abnormal
256 spirometry results.

257 **Correlation between chest radiographs and 6MWT with lung function.** 125 (58.1%) out of
258 215 subjects with abnormal chest CT at the follow-up had abnormalities in spirometry test. 89
259 subjects (71.2%) had restrictive pattern, 30 subjects (24%) had mixed with mostly restrictive
260 pattern, while 6 subjects (4.8%) had obstructive pattern in spirometry.

261 The median 6MWT in participants with abnormal spirometry was 381 (310;416) meters,
262 significantly different from participants with normal spirometry (400 (350;450) meters, $P =$
263 0.004). 14 subjects (77.8%) out of 18 subjects with specific respiratory symptoms, including
264 wheezing, dry cough, and cough with sputum, had abnormalities in chest CT at the follow-up.
265 Meanwhile, 32 (68.9%) out of 45 subjects with dyspnea on exertion and 15 (83.3%) out of 18
266 subjects with dyspnea on rest had abnormal chest CT scan.

267

268 **3.4 Cardiac screening**

269 All 312 participants underwent a cardiac screening (**Table 3**). Sinus bradycardia <50 bpm was
270 present in 4 participants (1.28%). 37 participants (11.9%) had higher NT-pro BNP levels ($>$
271 125pg/ml) and left ventricular ejection fraction was decreased in 50 participants (1.60%). The
272 most common cardiac abnormality was decreased diastolic function of the left ventricle (122,
273 39.1%). Left ventricular hypertrophy was present in all those participants. 50 (15.5%) had left
274 ventricular hypertrophy, and 40 of them had preexisting hypertension. Meanwhile, 9 participants
275 (18%) out of 50 with left ventricular hypertrophy did not have any cardiovascular comorbidities
276 before the follow-up. Seven participants of those had left ventricular hypertrophy and diastolic
277 dysfunction of LV, while 2 participants had dilatation of the left atrium in addition to left
278 ventricular hypertrophy and diastolic dysfunction.

279 Holter ECG revealed heart rhythm disturbances in 9 participants for the first time (2.88%),
280 including atrial fibrillation (4, 1.28%), AB block II degree (3, 0.96%), SA block (1, 0.32%), and
281 RBBB (1, 0.32%). The median age of patients with the first onset of rhythm disturbances was 69
282 years (IQR, 12), and no difference in gender was found. 2 patients with new-onset AF had
283 preexisting hypertension, and one patient had newly reported hypertension at the follow-up.

284 The mean systolic blood pressure (SBP) of all participants was 120.7 ± 16 mm Hg, and the mean
285 diastolic blood pressure (DBP) was 78.4 ± 9.03 mmHg with no significant difference between
286 females and males. Participants with elevated sBP defined as ≥ 140 mmHg were present in 71
287 subjects (22.8%).

288 24-hour blood pressure monitoring revealed 19 patients (6.10%) with elevated blood pressure
289 either in the daytime or nighttime for the first time. The median age of participants with new-
290 onset hypertension was 45 years (IQR, 12). One participant was pregnant during the screening,
291 and none of the patients had cardiovascular conditions before the follow-up time. Two patients

292 had type 2 diabetes. One patient had LV hypertrophy, 7 had diastolic dysfunction of LV, one
 293 patient had dilation of RA, and one patient was with dilation with LA.

294
 295 **Table 3.** Cardiac abnormalities detected in cardiac assessment of post-COVID-19 patients.

Serum cardiac biomarker	Total	
NT-proBNP > 125pg/ml	37 (11.9)	
Electrocardiography		
Sinus bradycardia <60bpm	26 (8.33)	
Sinus bradycardia <50bpm	4 (1.28)	
	Total	Newly diagnosed
Echocardiography		
Left ventricular ejection fraction [†] , %	61±4.55	
Left ventricular ejection fraction <50%	5 (1.60)	
Left ventricular hypertrophy	50 (15.5)	7 (2.24)
Diastolic dysfunction of left ventricle	122 (39.1)	2 (0.64)
Dilation of right atrium	2 (0.64)	1 (0.32)
Dilation of left atrium	12 (3.85)	
Holter electrocardiography		
Atrial Fibrillation	5 (1.60)	4 (1.28)
AV block II degree	4 (0.32)	3 (0.96)
Sinoatrial block	1 (0.32)	1 (0.32)
RBBB	1 (0.32)	1 (0.32)
24-hr BPM		
Mean SBP ≥140mmHg	71 (22.8)	19 (6.10)
Mean DBP ≥90 mm Hg	49 (15.7)	19 (6.10)
Note. – Except where indicated, data are numbers of participants, with percentages in parentheses. 24-hr BPM – 24-hour blood pressure monitoring † data are means ± standard deviation		

296
 297 Cardiac abnormalities in patients with hypertension and diabetes type 2 compared to
 298 participants with no comorbidities are shown in **Figure 5B** and **5C** respectively. 24-hour blood
 299 pressure monitoring revealed significantly higher systolic and diastolic blood pressure, left
 300 ventricular hypertrophy and elevated NT-proBNP in participants with hypertension and subjects
 301 with type 2 diabetes. Left ventricular diastolic dysfunction more frequently present in patients
 302 with hypertension.
 303

304 **Laboratory results.** The results of blood laboratory analysis at the follow-up are reported
 305 in **Table 4** and **Figures 2-4**. The minority of subjects had persistent inflammatory markers at the
 306 follow-up, including neutrophilia in 18 subjects (5.77%) and increased CRP levels in 54 subjects
 307 (17.3%). 28 subjects (8.97%) had leukopenia with WBC < 4x10⁹/l and 13 subjects (4.17%) had
 308 lymphopenia with lymphocytes<1.18x 10³/l.

309 Immunological test results showed that SARS-CoV19 IgM antibodies were present in 9 subjects
 310 (2.88%). Among those, 5 participants had follow-up at 5th months after the onset of the disease,
 311 while the other 4 participants had follow-up at 6th months. SARS-CoV19 IgG antibodies were
 312 present in 241 subjects (77.2%) and were <10 AH/ml in 71 participants (22.8%). Meanwhile,
 313 increased CMV IgG titers defined as >0.5 U/ml were present in almost all 312 participants.

314
 315 **Table 4.** Laboratory results of blood sample in participants after COVID-19 infection with
 316 median follow-up of 6 months.

	Normal range	Total (n=312)		Female (n=211)	Male (n=101)	P-value
		Media n (IQR)	n (%)			
WBC (x 10 ⁹ /l)	4.5 - 11	5.73 (6.67;4.85)		5.68 (4.71;6.74)	5.84 (5.1;6.52)	0.354
<4			28 (8.97)			
4-11			282 (90.38)			
>11			2 (0.64)			
NEUT (x 10 ³ /l)	1.56 - 5.38	3.11 (2.49;3.9)		3.1 (2.43;3.92)	3.11 (2.55;3.73)	0.762
<1.56			5 (1.60)			
1.56-5.38			289 (92.6)			
>5.38			18 (5.77)			
LYMPH (x 10 ³ /l)	1.18 - 3.57	1.9 (1.62;2.28)		1.9 (1.56;2.28)	1.95 (1.71;2.26)	0.276
<1.18			13 (4.17)			
1.18-3.57			291 (93.3)			
>3.57			8 (2.56)			
HGB (g/l)	120 - 160	134 (126;143)		129 (123;135)	148 (141;153)	0.000
<120			34 (10.9)			
PLT (x 10 ⁹ /l)	140 - 400	265 (314;230)		271 (236;327)	254 (219;296)	0.006

<140 140-400 >400			9 (2.88) 288 (92.3) 15 (4.81)			
CRP (mg/dl) >0.5	0 – 0.5	0.19 (0.09;0.41)		0.19 (0.08;0.48)	0.18 (0.09;0.34)	0.509
			54 (17.3)			
Creatinine (mg/dl) <0.67 0.67-1.17 >1.17	0.67 - 1.17	0.81 (0.71;0.94)		0.75 (0.68;0.84)	0.96 (0.86;1.08)	0.000
			50 (16.0) 250 (80.1) 12 (3.85)			
ALT (U/l) ≤50 >50	0 - 50	18.9 (12.2;26.9)		17.63 (12.0;24.6)	20.35 (13.9;33.7)	0.018
			287 (91.9) 25 (8.01)			
Glucose (mg/dl) <74 74-106 >106	74 - 106			92 (84.2;101.4)	94 (86.4;105)	0.213
			10 (3.21) 234 (75.00) 68 (21.8)			
Ferritin (ug/l) <30 30-400 >400	30 - 400	82.9 (35.3;156)		62 (20.8;107)	148.7 (86.7;222)	0.000
			72 (23.1) 228 (73.1) 12 (3.85)			
Fibrin ogen (g/l) <2 2-3.93 >3.93	2 - 3.93	3.49 (2.99;4.04)		3.56 (3.02;4.04)	3.34 (2.82;4.04)	0.112
			3 (0.96) 220 (70.5) 89 (28.5)			
D- dimer (mg/l) 0-0.50 >0.50	0 – 0.50	0.23 (0.19;0.36)		0.25 (0.19;0.37)	0.19 (0.19;0.31)	0.017
			269 (86.2) 43 (13.8)			
Urea	17-43	29.5		30	29.2	0.301

(mg/dl)		(24.1;36)		(24.5;36.2)	(23.8;35.1)	
>43			22 (7.05)			
Vitamin B12 (pg/ml)	182-820	475.1 (348;602)		493.3 (368.3;621.9)	418 (312.9;563)	0.021
<182			24 (7.69)			
182-820			252 (80.8)			
>820			36 (11.6)			
Vitamin D (ng/ml)	30-100	18.33 (11.1;30.6)		20.3 (11.5;32.2)	15.7 (10.1;28.4)	0.024
<30			232 (74.4)			
≥30			80 (25.6)			
Hb1Ac (%)	4.8-5.9	5.4 (5.1;5.7)		5.3 (5;5.7)	5.5 (5.15;5.85)	0.032
>5.9			59 (18.9)			
Total cholesterol (mmol/l)	<5.2	4.89 (4.29;5.52)		4.90 (4.31;5.63)	4.87 (4.17;5.38)	0.442
>5.2			100 (32.1)			
SARS COV IgM	0-10	0.54 (0.35;1.18)		0.61 (0.36;1.21)	0.48 (0.30;1.07)	0.036
>10			9 (2.88)			
SARS CoV IgG (AH/ml)	0-10	34.39 (12.5;66.1)		34.6 (12.2;65.1)	31.1 (13.1;68.6)	0.871
<10			71 (22.8)			
CMV IgM (COI)	0-0.7	0.16 (0.14;0.23)		0.17 (0.14;0.25)	0.15 (0.14;0.19)	0.090
>0.7			14 (4.49)			
CMV IgG (U/ml)	0-0.5	490 (233;500)		500 (277;500)	446 (183;500)	0.142
>0.5			308 (99.0)			
Note.— <i>P</i> values comparing female and male participants were determined with the Mann-Whitney <i>U</i> test.						

WBC – white blood cells
NEUT – neutrophils
LYMPH – lymphocytes
HGB – hemoglobin
PLT – platelets
ESR – erythrocyte sedimentation rate
CRP – C-reactive protein

317

318 **4. Discussion**

319 In our study 6 months after acute illness with COVID-19, most of patients still meet the criteria
320 for long COVID-19 and show at least one persistent symptom. These results are mainly in line
321 with studies reporting the prevalence of long COVID-19 in patients 3 to 6 months after COVID-
322 19 (Al-Aly et al., 2021; Huang C et al., 2021; Nasserie et al., 2021; Nehme et al., 2021). Long-
323 Covid-19 symptoms have similarities with chronic fatigue syndrome developed after viral
324 infections (Holmes et al., 1988; Hickie et al., 2006) and may afflict a wide range of organs, with
325 the most common symptoms being chronic fatigue, shortness of breath, cognitive impairments
326 (Cares-Marambio et al., 2021; Shah et al., 2021; Davido et al., 2020; Halpin et al., 2020).

327 The pathophysiology of long COVID-19 respiratory and multi-organ sequelae has a
328 fundamental knowledge gap that must be addressed (Lerner et al., 2021). Viral infections are
329 considered to be cofactors for the initiation and exacerbation of lung fibrosis (Naik, Moore,
330 2010), and clinical evidence suggesting cardiovascular involvement has been reported for
331 essentially all known viral infections (Abelmann, 1971). Observational studies revealed a high
332 percentage of post-COVID-19 sequelae such as respiratory problems, lung fibrosis (Lechowicz
333 et al., 2020; Ali et al., 2021), and cardiovascular problems (Bose, McCarthy, 2020). Moreover,
334 long COVID-19 affects even mild-to-moderate cases of survivors of COVID-19 with pulmonary
335 sequelae reported after recovery (Wang et al., 2020). Secondly, our study demonstrated that
336 deranged blood indices (increased neutrophils, WBC, changed coagulation profile-significantly
337 increased DD; fasting glucose, HbA1c, HGB) and raised inflammatory marker (CRP) are
338 associated with pre-existing comorbidities, specifically, hypertension and diabetes. HbA1c is
339 considered the gold standard for evaluating blood glucose levels (Nalysnyk et al., 2010) and is
340 considered to be associated with inflammation, hypercoagulability, blood oxygen saturation, and
341 higher mortality rate in COVID-19 patients (Wang et al., 2020).

342 Hypertension affects more than a quarter of the global population (Kearney et al., 2005;
343 Forouzanfar et al., 2017), has been identified as a major risk factor for COVID-19 severity
344 (Liang et al., 2020; Madhur et al., 2021) and higher risk of dying from COVID-19 (Gao et al.,
345 2020). Moreover, hypertension is closely associated with other comorbidities, predominantly
346 obesity and diabetes, and significantly affects inflammation (Jayedi et al., 2019). In this study,
347 hypertension, besides the above-mentioned significant changes in blood and inflammatory
348 markers that coincided with other comorbidities (diabetes), also revealed significant changes in
349 fibrinogen (Fbg) and ferritin levels. Changes in Fbg levels can be associated with a substantial
350 rearrangement in blood vessel walls observed in individuals with pre-existing hypertension. The
351 abnormal Fbg levels have a strong association to COVID-19 disease severity (rev. Len et al.,
352 2022), and assessment of Fbg levels at admission is important for determining of prognosis of
353 COVID-19 patients (Long et al., 2021). Abnormal Fbg levels are observed in post-COVID-19
354 cohorts by different groups (Tartari et al., 2021). Cardiovascular changes associated with

355 COVID-19 may lead to left ventricular dysfunction (Medranda et al., 2021), which in our cohort
356 had a higher prevalence in convalescent patients with hypertension.

357 Cardiac screening showed a mean ejection fraction $61 \pm 4.55\%$, which is less than in
358 participants observed 1-4 weeks after discharge (Zhou, 2021). This can be explained by a higher
359 prevalence of chronic heart diseases, including hypertension and CAD, in our cohort of
360 participants. Interestingly, our study revealed new cases of left ventricular hypertrophy and
361 diastolic dysfunction of LV in participants with no preexisting cardiovascular disorders. In
362 addition, 19 participants had newly diagnosed hypertension during the follow-up. The patients
363 with newly diagnosed hypertension were young (median, 45 years) and had no preexisting
364 cardiovascular comorbidities before the follow-up. However, echocardiography revealed long-
365 term complications in some of those patients, meaning that hypertension might have been before
366 the 6-month follow-up and COVID-19 infection. In addition to hypertension and LV
367 dysfunction, our study found 9 new cases of rhythm disturbances detected in 24-hour BP
368 monitoring. Newly detected rhythm disturbances included atrial fibrillation (AF), AB block II
369 degree, sinoatrial (SA) block, and RBBB (**Table 3**).

370 Although our cohort was limited to establishing the time of the onset of hypertension in the
371 post-COVID-19 period, our findings in patients with no preexisting cardiac comorbidities and
372 standard echocardiography suggest the presence of the long-term effect of COVID-19 on cardiac
373 function. The evidence of cardiac injury in post-COVID-19 patients (left ventricular ejection
374 fraction and diastolic dysfunction) and the appearance of arrhythmias corroborate with the
375 findings of other investigators (rev. Satterfield et al., 2022; Tudoran et al., 2022). The
376 arrhythmias in post-COVID patients were found to be associated with COVID-19 disease
377 severity (Mohammad et al., 2021).

378 In patients with COVID-19, the viral infection may initiate inflammation with subsequent
379 fibrosis, and cardiac inflammation and fibrosis are major pathological mechanisms leading to
380 heart failure (Suthahar et al., 2017). Non-invasive imaging, blood analysis for fibrosis markers,
381 and endomyocardial biopsy (EMB) are used to detect fibrosis (Raafs et al., 2021). The primary
382 imaging technique in contemporary heart failure management is echocardiography; however, it
383 provides little information about the extent of fibrosis (de Boer et al., 2019). To evaluate the
384 cardiac and lung changes we used echocardiography and the chest CT.

385 The question if the lung is a target organ for diabetes mellitus has been discussed, and a body
386 of clinical and experimental evidence indicates that fibrosis and other pulmonary complications
387 are more prevalent than it was early recognized (Sandler, 1990; Hsia, Raskin, 2005; Yang et al.,
388 2011). Critically fibrotic changes on follow-up CT scans were significantly associated with
389 hypertension but not diabetes (**Figure 5**). The presence of diabetes and new-onset diabetes was
390 an independent factor associated with poor outcomes during different coronavirus infections –
391 SARS-CoV-1 (Yang et al., 2006), MERS-CoV (Alraddadi et al., 2016), and SARS-CoV-2 (rev.
392 Singh, Singh, 2020). In our study, hypertension had a significant association with fibrotic
393 changes on CT-scan, whereas diabetes type II did not. One of the possible explanations can be a
394 small percentage of patients with diabetes type II in our Long COVID-19 cohort. However, we
395 may also speculate that the fibrotic changes in post-COVID-19 develop faster when blood
396 vessels are already affected by hypertension. It was reported that abnormal lung CT findings
397 could present even in asymptomatic or mild COVID-19 patients (Shi et al., 2020). The
398 association of radiological CT findings with hypertension in Long COVID-19 makes
399 hypertension, in combination with other results (high fibrinogen, DD, etc.), a possible early
400 marker of developing fibrotic lung changes.

401 Laboratory tests identified the long-term persistence of IgM antibodies in 9 patients from our
402 cohort (5-6 months). The IgM antibodies at COVID-19 infection peak early and rapidly decline
403 (rev. Huang AT et al., 2020; Mallon et al., 2021; Štěpánek et al., 2022). IgM seropositivity was
404 found to be correlating with a symptom duration (Štěpánek et al., 2022). Moreover, the long-
405 term persistence of anti-SARS-CoV-2 IgM antibodies was recently reported by Bichara and
406 colleagues (2021), who observed a long 8-months persistence of the IgM antibodies after
407 COVID-19 infection in two patients. The prolonged persistence of anti-viral IgM antibodies was
408 described after different acute viral infections and live viral vaccines: the Japanese encephalitis
409 live vaccine (Hills et al., 2021), acute hepatitis A infection (Kao et al., 1984), dengue virus
410 infection (Chien et al., 2018), Zika virus > 2 years (Griffin et al. 2019), yellow fever virus
411 vaccine > 3-4 years (Gibney et al., 2012), and in cerebrospinal liquid and blood of patients after
412 West Nile virus infection (Kapoor et al., 2004; Roehrig et al., 2003; Papa et al., 2011; Murray et
413 al., 2013) in some cases up to 8 years after infection. The finding of long persistence of IgM
414 antibodies in some participants of the post-COVID-19 cohort warrants additional investigation,
415 particularly the determination of whether persistence of IgM is related to persistent infection
416 with SARS-CoV2. However, the finding of elevated IgG anti-CMV antibodies in most of the
417 cohort should be interpreted with caution due to the possibility of cross-reactivity between viral
418 epitopes and human tissue antigens (Kreye et al., 2020; Vojdani et al., 2021).

419 According to Chalder Fatigue Score, the prevalence of some symptoms, as well as
420 neurological symptoms had a significant association with the female gender. This finding
421 corroborates the recent conclusions of another prospective study of Long COVID-19 syndrome
422 (Bai et al., 2022).

423 There are several limitations of our study: (1) Patients only with persistent symptoms were
424 selected for the study, and there was no control group for comparison of patients with and
425 without the Long COVID-19 syndrome; (2) The absence of baseline health data and CT-imaging
426 data before the infection and before the mean of 6 months of follow-up limits the assessment of
427 changes in patient's results; (3) Social information of patients, including the number of years of
428 smoking, alcohol use, and lifestyle, was not reported, which might have a confounding effect on
429 some of the results. We did not include in the asymptomatic cohort individuals with a mild
430 phenotype of disease though non-hospitalized subjects with moderate post-COVID-19 were
431 included; (4) We had some limitations on cardiovascular measures. It would not be appropriate
432 or feasible to obtain histological data from otherwise healthy subjects. The data in this study
433 permit a 6-months assessment of Long-COVID-19 sequelae. Long-term prospective studies of
434 longer duration are still needed.

435

436 **5. Conclusions**

437 In the 6-months follow up Long COVID-19 cohort, among the tested parameters, those
438 positively correlated with comorbid conditions include age, BMI, D-dimers, NT-proBNP, C-
439 reactive protein, neutrophils, fasting glucose, and HbA1c; hypertension also shows three
440 associations that were not found in patients when examining the role of diabetes: increased
441 hemoglobin, fibrinogen, and ferritin. In addition to hypertension and LV dysfunction, our study
442 found new cases of rhythm disturbances detected in 24-hour BP monitoring that included atrial
443 fibrillation (AF), AB block II degree, sinoatrial (SA) block, and RBBB. We speculate that due to
444 the significant association of hypertension with CT fibrotic changes, it may serve as an early
445 predictive marker (in combination with high Fbg and DD) for the development of lung
446 parenchymal diseases in post-COVID-19.

447 With the new outbreaks of SARS-CoV-2 infection in many countries, it is expected that the
448 patients' burden having Long COVID-19 respiratory and cardiovascular sequelae is going to
449 increase and lead to another public health crisis following the current pandemic. Thus, it is vital
450 for further research comprising longer-ranging observational studies critical to evaluate the long-
451 term consequences of COVID-19. The preliminary study presented here can be prolonged to 12
452 and 24 follow-ups. This will enable us to study the long-term effects of Long COVID-19 and
453 identify symptoms significant for medical treatment and observation.

454

455 **References**

456 Abelmann WH. Virus and the heart. *Circulation* (1971) 44: 950-956.

457 Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-
458 19. *Nature* (2021) 594:259–64. <http://dx.doi.org/10.1038/s41586-021-03553-9>.

459 Ali RMM, Ghonimy MBI. Post-COVID-19 pneumonia lung fibrosis: A worrisome sequelae in
460 surviving patients. *Egypt. J. Radiol. Nucl. Med.* (2021) 52: 101. [https://doi.org/10.1186/s43055-](https://doi.org/10.1186/s43055-021-00484-3)
461 021-00484-3.

462 Alraddadi BM, Watson JT, Almarashi A, Abedi GR, Turkistani A, et al. Risk factors for primary
463 Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. *Emerging*
464 *Infect. Dis.* (2016) 22:49. doi: 10.3201/eid2201.151340.

465 American College Cardiology. Coronavirus Disease 2019 (COVID-19) Provides Potent
466 Reminder of the Risk of Infectious Agents. 2020. [https://www.acc.org/latest-in-](https://www.acc.org/latest-in-cardiology/articles/2020/03/01/08/42/feature-coronavirus-disease-2019-covid-19-providespotent-reminder-of-the-risk-of-infectious-agents)
467 [cardiology/articles/2020/03/01/08/42/](https://www.acc.org/latest-in-cardiology/articles/2020/03/01/08/42/feature-coronavirus-disease-2019-covid-19-providespotent-reminder-of-the-risk-of-infectious-agents)
468 [feature-coronavirus-disease-2019-covid-19-](https://www.acc.org/latest-in-cardiology/articles/2020/03/01/08/42/feature-coronavirus-disease-2019-covid-19-providespotent-reminder-of-the-risk-of-infectious-agents)
providespotent-reminder-of-the-risk-of-infectious-agents.

469 Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mulè G, Augello M, Mondatore D,
470 Allegrini M, Cona A, Tesoro D. Female gender is associated with long COVID syndrome: a
471 prospective cohort study. *Clinical Microbiol Infection* (2022) 28:611-e9.
472 <https://doi.org/10.1016/j.cmi.2021.11.002>.

473 Bichara CD, Amoras ES, Vaz GL, Bichara CN, Amaral IP, Vallinoto AC. Persistence of Anti-
474 SARS-CoV-2 IgM Antibody up to 8 Months Post-COVID-19. *Case Reports in Clinical*
475 *Medicine* (2021), 10:227-31. DOI: 10.4236/crcm.2021.109029.

476 Cares-Marambio K, Montenegro-Jimenez Y, Torres-Castro R, et al. Prevalence of potential
477 respiratory symptoms in survivors of hospital admission after coronavirus disease 2019
478 (COVID-19): A systematic review and meta-analysis. *Chron Respir Dis.* (2021)
479 18:14799731211002240.

480 Cheng L, Li H, Li L, Liu C, Yan S, Chen H, Li Y. Ferritin in the coronavirus disease 2019
481 (COVID-19): a systematic review and meta-analysis. *J Clin Laboratory Analysis* (2020) 34:
482 e23618. <https://doi.org/10.1002/jcla.23618>.

483 Chien YW, Liu ZH, Tseng FC, Ho TC, Guo HR, Ko NY, Ko WC, Perng GC. Prolonged
484 persistence of IgM against dengue virus detected by commonly used commercial assays. *BMC*
485 *Infect Dis* (2018) 18:1-7. <https://doi.org/10.1186/s12879-018-3058-0>.

- 486 Cuomo G, Puzzolante C, Iadisernia V, Santoro A, Menozzi M, et al. Development of post-
487 COVID-19 cardiovascular events: an analysis of clinical features and risk factors from a single
488 hospital retrospective study. *UNIMORE IRIS* (2021) 2021: 538-549.
- 489 Das KM, Lee EY, Singh R, et al. Follow-up chest radiographic findings in patients with MERS-
490 CoV after recovery. *Indian J Radiol Imaging* (2017) 27:342–349. DOI:
491 10.4103/ijri.IJRI_469_16.
- 492 de Almeida-Pititto B, Dualib PM, Zajdenverg L, Dantas JR, De Souza FD et al. Severity and
493 mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a
494 meta-analysis. *Diabetology & Metabolic Syndrome* (2020) 12:75 [https://doi.org/10.1186/s13098-](https://doi.org/10.1186/s13098-020-00586-4)
495 020-00586-4.
- 496 de Boer RA, De Keulenaer G, Bauersachs J, Brutsaert D, Cleland JG et al. Towards better
497 definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the
498 Committee of Translational Research of the Heart Failure Association (HFA) of the European
499 Society of Cardiology. *European J of Heart Failure* (2019) 21:272-85.
500 <https://doi.org/10.1002/ejhf.1406>.
- 501 Davido B, Seang S, Tubiana R, de Truchis P. Post–COVID-19 chronic symptoms: a
502 postinfectious entity? *Clin Microbiol Infect.* (2020) 26:1448–9.
503 <https://doi.org/10.1016/j.cmi.2020.07.028>.
- 504 Deng Q, Hu B, Zhang Y, Wang H, et al. Suspected myocardial injury in patients with COVID-
505 19: Evidence from front-line clinical observation in Wuhan, China. *Int J Cardiol.* (2020) 311:
506 116-121. <https://doi.org/10.1016/j.ijcard.2020.03.087>.
- 507 Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, et al. Association of hypertension and
508 antihypertensive treatment with COVID-19 mortality: a retrospective observational
509 study. *European Heart J* (2020) 41: 2058-2066. <https://doi.org/10.1093/eurheartj/ehaa433>.
- 510 Fabri L, Moss, S, Khan F, Chi W, Xia J. 2021. Post-viral parenchymal lung disease following
511 COVID-19 hospitalization: a systematic review and meta-analysis. MedRxiv
512 doi: <https://doi.org/10.1101/2021.03.15.21253593> (Accepted, *Thorax*).
- 513 Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of
514 hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. *JAMA*
515 (2017) 317: 165–82. doi:10.1001/jama.2016.19043.
- 516 Fortini A, Torrigiani A, Sbaragli S, Lo Forte A, Crociani A, Cecchini P, et al. COVID-19:
517 persistence of symptoms and lung alterations after 3–6 months from hospital discharge. *Infection*
518 (2021) 49: 1007-1015. <https://doi.org/10.1007/s15010-021-01638-1>.
- 519 Fumagalli A, Misuraca C, Bianchi A, Borsa N, Limonta S, Maggiolini S et al. 2021 Long-term
520 changes in pulmonary function among patients surviving to COVID-19 pneumonia. *Infection*
521 (2021): 1-4. <https://doi.org/10.1007/s15010-021-01718-2>.
- 522 Furukawa NW, Brooks JT, Sobel J. Evidence supporting transmission of severe acute respiratory
523 syndrome coronavirus 2 while pre-symptomatic or asymptomatic. *Emerg Infect Dis* (2020) 26:
524 e201595. doi: 10.3201/eid2607.201595.

- 525 Gibney KB, Edupuganti S, Panella AJ, Kosoy OI, Delorey MJ, Lanciotti RS, Mulligan MJ,
526 Fischer M, Staples JE. Detection of anti-yellow fever virus immunoglobulin M antibodies at 3–4
527 years following yellow fever vaccination. *American J Tropical Med Hygiene* (2012) 87:1112.
- 528 Griffin I, Martin SW, Fischer M, Chambers TV, Kosoy OL, Goldberg C, Falise A, Villamil V,
529 Ponomareva O, Gillis LD, Blackmore C. Zika virus IgM 25 months after symptom onset, Miami-
530 Dade county, Florida, USA. *Emerging Infect Dis.* (2019) 25:2264. doi: 10.3201/eid2512.191022.
- 531 Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms
532 and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. *J Med*
533 *Virol* (2020) 2020:1–10. <https://doi.org/10.1002/jmv.26368>.
- 534 Han H, Xie L, Liu R, et al. Analysis of heart injury laboratory parameters in 273 COVID-19
535 patients in one hospital in Wuhan, China. *J Med Virol.* (2020) 92: 819-23.
536 <https://doi.org/10.1002/jmv.25809>.
- 537 Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, et al. Post-infective and
538 chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort
539 study. *BMJ* 333: 575 (2006). doi: <https://doi.org/10.1136/bmj.38933.585764.AE>.
- 540 Hills SL, Van Keulen A, Feser J, Panella A, Letson GW, Staples JE, Marfin AA, Brault AC.
541 Persistence of IgM antibodies after vaccination with live attenuated Japanese encephalitis
542 vaccine. *American J Tropical Med Hygiene* (2021) 104:576. doi: 10.4269/ajtmh.20-1132.
- 543 Holmes GP, Kaplan JE, Gantz NM, Komaroff, AL, Schonberger LB, et al. Chronic fatigue
544 syndrome: a working case definition. *Annals Internal Med* (1988) 108:387-389.
545 <https://doi.org/10.7326/0003-4819-108-3-387>.
- 546 Hsia CC, Raskin P. The diabetic lung: relevance of alveolar microangiopathy for the use of
547 inhaled insulin. *American J Medicine* (2005)118: 205-11.
548 <https://doi.org/10.1016/j.amjmed.2004.09.019>.
- 549 Huang AT, Garcia-Carreras B, Hitchings MD, Yang B, Katzelnick LC, et al. A systematic
550 review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and
551 association with severity. *Nature Comm* (2020) 11:1-6. [https://doi.org/10.1038/s41467-020-](https://doi.org/10.1038/s41467-020-18450-4)
552 18450-4.
- 553 Huang C, Huang L, Wang Y, Li X, Ren L, Gu X 6-month consequences of COVID-19 in
554 patients discharged from hospital: a cohort study. *Lancet* (2021) 397:220-32.
555 doi: [http://dx.doi.org/10.1016/S0140-6736\(20\)32656-8](http://dx.doi.org/10.1016/S0140-6736(20)32656-8).
- 556 Jayedi A, Rahimi K, Bautista LE, Nazarzadeh M, Zargar MS, et al. Inflammation markers and
557 risk of developing hypertension: a meta-analysis of cohort studies. *Heart* (2019) 105: 686-692.
558 doi: 10.1136/heartjnl-2018-314625.
- 559 Kao HW, Ashcavai M, Redeker AG. The persistence of hepatitis A IgM antibody after acute
560 clinical hepatitis A. *Hepatology* (1984) 4: 933-936. <https://doi.org/10.1002/hep.1840040525>.
- 561 Kapoor H, Signs K, Somsel P, Downes FP, Clark PA, Massey JP. Persistence of West Nile Virus
562 (WNV) IgM antibodies in cerebrospinal fluid from patients with CNS disease. *J Clin Virol*
563 (2004) 31:289-91. <https://doi.org/10.1016/j.jcv.2004.05.017>.

- 564 Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of
565 hypertension: analysis of worldwide data. *Lancet* (2005) 365:217–23.
566 [https://doi.org/10.1016/S0140-6736\(05\)17741-1](https://doi.org/10.1016/S0140-6736(05)17741-1).
- 567 Kreye J, Reincke SM, Prüss H. Do cross-reactive antibodies cause neuropathology in COVID-
568 19? *Nat Rev Immunol.* (2020) 20:645–646. <https://doi.org/10.1038/s41577-020-00458-y>.
- 569 Lechowicz K, Drozd`zal S, Machaj F, Rosik J, Szostak B et al. COVID-19: The potential
570 treatment of pulmonary fibrosis associated with SARS-CoV-2 infection. *JCM* (2020) 9: 1917.
571 <https://doi.org/10.3390/jcm9061917>.
- 572 Len P, Iskakova G, Sautbayeva Z, Kussanova A., Taeukelova AT et al. 2022. Meta-analysis and
573 systematic review of coagulation disbalances in COVID-19: 41 studies and 17,601 patients.
574 *Frontiers Cardiovascular Med* 9: 794092. doi: 10.3389/fcvm.2022.794092.
- 575 Lerner AM, Robinson DA, Yang L, et al. 2021. Toward understanding COVID-19 recovery:
576 National Institutes of Health workshop on postacute COVID-19. *Ann Intern Med*, 174: 999-
577 1003.
578 <https://doi.org/10.7326/M21-1043>.
- 579
- 580 Leth S, Gunst JD, Mathiasen V, Hansen K, S`ogaard O, `Ostergaard L, Jensen-Fangel S, Storgaard
581 M, Agergaard J. Persistent symptoms in patients recovering from COVID-19 in Denmark. *Open*
582 *Forum Infectious Dis* (2021) 8: ofab042). US: Oxford University Press.
583 <https://doi.org/10.1093/ofid/ofab042>.
- 584
- 585 Li Y, Li H, Zhu S, Xie Y, Wang B, He L, et al. Prognostic value of right ventricular longitudinal
586 strain in patients with COVID-19. *Cardiovascular Imaging* (2020) 13:2287–2299.
587 <https://doi.org/10.1016/j.jcmg.2020.04.014>.
- 588 Liang X, Shi L, Wang Y, Xiao W, Duan G, et al. The association of hypertension with the
589 severity and mortality of COVID-19 patients: evidence based on adjusted effect estimates. *J.*
590 *Infect.* (2020) 81: e44–e47. DOI: <https://doi.org/10.1016/j.jinf.2020.06.060>.
- 591 Long W, Yang J, Li Z, Li J, Chen S, Chen D, Wang S, Li Q, Hu D, Huang J, Zeng W. Abnormal
592 fibrinogen level as a prognostic Indicator in coronavirus disease patients: a retrospective cohort
593 study. *Frontiers in Med.* (2021) 8:687220. doi: 10.3389/fmed.2021.687220.
- 594 Madhur MS, Eljovich F, Alexander MR, Pitzer A, Ishimwe J, et al. Hypertension. Do
595 inflammation and immunity hold the key to solving this epidemic? *Circ Res* (2021) 128: 908-
596 933. DOI: 10.1161/CIRCRESAHA.121.318052.
- 597 Mallon PW, Tinago W, Leon AG, McCann K, Kenny G, et al. Dynamic change and clinical
598 relevance of postinfectious SARS-CoV-2 antibody responses. In: *Open Forum Infectious*
599 *Diseases* (2021) 8: ofab122. US, Oxford University Press. <https://doi.org/10.1093/ofid/ofab122>.
- 600 Mancía, G., Rea, F., Ludergnani, M., Apolone, G. & Corrao, G. Renin – angiotensin–aldosterone
601 system blockers and the risk of Covid-19. *N. Engl. J. Med.* (2020) 382: 2431–2440. DOI:
602 10.1056/NEJMoa2006923.
- 603 Medranda GA, Fazlalizadeh H, Case BC, Yerasi C, Zhang C, et al. 2021. Implications of left
604 ventricular function on short-term outcomes in COVID-19 patients with myocardial

- 605 injury. *Cardiovascular Revascularization Med* (2021) 29: 45-49.
606 <https://doi.org/10.1016/j.carrev.2021.03.028>.
- 607 Mineo G, Ciccamese F, Modolon C, Landini MP, Valentino M, Zompatori M. Post-ARDS
608 pulmonary fibrosis in patients with H1N1 pneumonia: role of follow-up CT. *Radiol Med*
609 (*Torino*) (2012) 117:185–200. <https://doi.org/10.1007/s11547-011-0740-3>.
- 610 Mohammad M, Emin M, Bhutta A, Gul EH, Voorhees E, Afzal MR. Cardiac arrhythmias
611 associated with COVID-19 infection: state of the art review. *Expert Rev Cardiovascular Therapy*
612 (2021), 19: 881-889. <https://doi.org/10.1080/14779072.2021.1997589>.
- 613 Murray KO, Garcia MN, Yan C, Gorchakov R. Persistence of detectable immunoglobulin M
614 antibodies up to 8 years after infection with West Nile virus. *American J Tropical Med Hygiene*
615 (2013) 89:996. doi: 10.4269/ajtmh.13-0232.
- 616 Naik, P.K., Moore, B.B. Viral infection and aging as cofactors for the development of pulmonary
617 fibrosis. *Expert Rev Respiratory Med* (2010) 4: 759-771. <https://doi.org/10.1586/ers.10.73>.
- 618 Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in
619 patients with diabetes mellitus: evidence from a systematic review of the literature. *Diabetes*
620 *Obes Metab* (2010) 12:288-298. <https://doi.org/10.1111/j.1463-1326.2009.01160.x>.
- 621 Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent
622 symptoms among patients with COVID-19: a systematic review. *JAMA network open*.
623 2021;4(5): e2111417. doi: <http://dx.doi.org/10.1001/jamanetworkopen.2021.11417>.
- 624 Nehme M, Braillard O, Alcoba G, Aebischer Perone S, Courvoisier D, Chappuis F. COVID-19
625 symptoms: longitudinal evolution and persistence in outpatient settings. *Ann Intern Med*.
626 (2021)174(5):723-5. doi: <http://dx.doi.org/10.7326/M20-5926>.
- 627 Navarro AO, Cervantes-Bojalil J, Quevedo ODJC, Martínez AA, Hernández-Jiménez CA, et al.
628 Decreased quality of life and spirometric alterations even after mild-moderate COVID-19. *Respir*
629 *Med*. (2021) 181:106391. <https://doi.org/10.1016/j.rmed.2021.106391>.
- 630 Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased
631 mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis
632 and meta-regression. *J Renin-Angiotensin-Aldosterone System: JRAAS* (2020) 21:
633 1470320320926899.
- 634 Raafs AG, Verdonschot JA, Henkens MT, Adriaans BP, Wang P et al. The combination of
635 carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium
636 enhancement at cardiac magnetic resonance provides additional prognostic information in
637 idiopathic dilated cardiomyopathy—A multilevel assessment of myocardial fibrosis in dilated
638 cardiomyopathy. *European J Heart Failure* (2021) 23:933-44. <https://doi.org/10.1002/ehhf.2201>.
- 639 Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post-acute sequelae of
640 COVID-19 with a cardiovascular focus. *European Heart J*. (2022) 43:1157-1172.
641 <https://doi.org/10.1093/eurheartj/ehac031>.
- 642 Roehrig JT, Nash D, Maldin B, Labowitz A, Martin DA, Lanciotti RS, Campbell GL.
643 Persistence of virus-reactive serum immunoglobulin M antibody in confirmed West Nile virus
644 encephalitis cases. *Emerging Infectious Dis*. (2003) 9:376. doi: 10.3201/eid0903.020531.

- 645 Sandler M. Is the lung a ‘target organ’ in diabetes mellitus? *Arch Intern Med* (1990) 150: 1385-
646 1388. doi:10.1001/archinte.1990.00390190051006.
- 647 Satterfield BA, Bhatt DL, Gersh BJ. Cardiac involvement in the long-term applications of
648 COVID-19. *Nature Rev Cardiology* (2022) 19: 332-341. [https://doi.org/10.1038/s41569-021-](https://doi.org/10.1038/s41569-021-00631-3)
649 00631-3.
- 650 Štěpánek L, Janošíková M, Štěpánek L, Nakládalová M, Boriková A. The kinetics and predictors
651 of anti-SARS-CoV-2 antibodies up to 8 months after symptomatic COVID-19: A Czech
652 cross-sectional study. *J Medical Virol* (2022) Epub Apr 14. <https://doi.org/10.1002/jmv.27784>.
- 653 Shah W, Hillman T, Playford ED, et al. Managing the long-term effects of Covid-19: summary
654 of NICE, SIGN, and RCGP rapid guideline. *BMJ* (2021) 372: n136.
655 doi: <https://doi.org/10.1136/bmj.n136>.
- 656 Shi H, Han X, Jiang N, Cao Y, Alwalid O, et al. Radiological findings from 81 patients with
657 COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infectious Dis.* (2020)
658 20:425-34. [https://doi.org/10.1016/S1473-3099\(20\)30086-4](https://doi.org/10.1016/S1473-3099(20)30086-4).
- 659 Shieh W-JBD, Blau DM, Denison AM, et al. 2009 pandemic influenza A (H1N1): pathology and
660 pathogenesis of 100 fatal cases in the United States. *Am J Pathol* (2010) 177:166–175.
661 <https://doi.org/10.2353/ajpath.2010.100115>.
- 662 Singh AK, Singh R. Hyperglycemia without diabetes and new-onset diabetes are both associated
663 with poorer outcomes in COVID-19. *Diabetes Res. Clinical Practice* (2020) 167:108382.
664 <https://doi.org/10.1016/j.diabres.2020.108382>.
- 665 Solomon JJ, Heyman B, Ko JP, Condos R, Lynch DA. CT of post-acute lung complications of
666 COVID-19. *Radiology* (2021) 2021: 211396. doi: 10.1148/radiol.2021211396.
- 667 Suthahar N, Meijers WC, Silljé HH, de Boer RA. From inflammation to fibrosis—molecular and
668 cellular mechanisms of myocardial tissue remodelling and perspectives on differential treatment
669 opportunities. *Current Heart Failure Reports* (2017) 14:235-250.
670 <https://doi.org/10.1007/s11897-017-0343-y>.
- 671 Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence
672 and treatment strategies. *Front Immunol* (2020) 11: 1708. doi: 10.3389/fimmu.2020.01708.
- 673 Tartari CJ, Milani G, Salvetti F, Marchetti M, Russo L, Vignoli A, Vitali M, Schieppati F,
674 Ravasio G, Castellani L, Sanga E. Post-Covid-19 hemostatic characteristics of convalescent
675 patients: The Bergamo Experience. *Blood* (2021)138(Suppl. 1):1054.
676 <https://doi.org/10.1182/blood-2021-153611>.
- 677 Trump S, Lukassen S, Anker MS, Chua RL, Liebig J. et al. 2021. Hypertension delays viral
678 clearance and exacerbates airway hyperinflammation in patients with COVID-19. *Nature*
679 *Biotechnol.* (2021) 39:705-716. <https://doi.org/10.1038/s41587-020-00796-1>.
- 680 Tudoran C, Tudoran M, Cut TG, Lazureanu VE, Oancea C, et al. Evolution of echocardiographic
681 abnormalities identified in previously healthy individuals recovering from COVID-19. *J*
682 *Personalized Med* (2022) 12:46. <https://doi.org/10.3390/jpm12010046>.

- 683 Vojdani A, Monro J, Lanzisera F, Sadeghi H. Serological cross-reactivity between viruses and
684 their contribution to autoimmunity. *Autoimmunity Rev.* (2021) 7:102840.
685 DOI: 10.1016/j.autrev.2021.102840.
- 686 Wang JY, Chang SY, Huang YW, Chang SC. Serology-positive but minimally symptomatic
687 COVID-19 may still cause lung injury and lung function impairment. *Int J Tuberc Lung Dis.*
688 (2020) 24:568-569. doi: 10.5588/ijtld.20.0197.
- 689 Wu Q, Zhong L, Li H, Guo J, Li Y, Hou X, et al. A follow-up study of lung function and chest
690 computed tomography at 6 months after discharge in patients with coronavirus disease 2019.
691 *Can Respir J.* (2021) 2021:6692409. <https://doi.org/10.1155/2021/6692409>.
- 692 Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, et al. Plasma glucose levels and diabetes are
693 independent predictors for mortality and morbidity in patients with SARS. *Diabetic Med.* (2006)
694 23:623-8. <https://doi.org/10.1111/j.1464-5491.2006.01861.x>.
- 695 Yang J, Xue Q, Miao L, Cai L. Pulmonary fibrosis: a possible diabetic complication.
696 *Diabetes/Metabolism Research and Rev.* (2011) 27:311-317. <https://doi.org/10.1002/dmrr.1175>.
- 697 Young SJ. Long-COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors
698 and treatments. *Infect Dis.* (2021) 53: 737-754. <https://doi.org/10.1080/23744235.2021.1924397>.
- 699 Zhang P, Li J, Liu H, Han N, Ju J, et al. Correction: Long-term bone and lung consequences
700 associated with hospital-acquired severe acute respiratory syndrome: A 15-year follow-up from a
701 prospective cohort study. *Bone Res.* (2020) 8: 1-8. <https://doi.org/10.1038/s41413-020-0084-5>.
- 702 Zhao Y-M, Shang Y-M, Song W-B, et al. Follow-up study of the pulmonary function and related
703 physiological characteristics of COVID-19 survivors three months after recovery.
704 *EClinicalMedicine* (2020) 25:100463. <https://doi.org/10.1016/j.eclinm.2020.100463>.
- 705 Zhou M, Wong C, Un K, Lau Y, Lee J, Tam F, et al. Cardiovascular sequelae in uncomplicated
706 COVID-19 survivors. *PLoS ONE* (2021) 16: e0246732. doi:10.1371/journal.pone.0246732.
707

708 **Acknowledgements**

709 This research has been funded by the Science Committee of the Ministry of Education and
710 Science of the Republic of Kazakhstan (Grant No. BR10965164). <https://www.ncste.kz/en/main>.
711 The funders had no role in study design, data collection and analysis, decision to publish, or
712 preparation of the manuscript.

713 **Authors' contributions**

714 AT, ZK, BA, NK, MB - Conceptualization, Investigation, Methodology, Supervision, Writing –
715 review & editing, AS, SK - Data curation, project administration. ZS, PL – Methodology,
716 Statistical analysis. NSB – Supervision, Analysis, Writing a draft. All authors read and edit a
717 final draft. All authors contributed to the article and approved the submitted version.

718 **Competing interests**

719 The authors declare no competing financial interests.

720 **Data Availability Statement**

721 There is a risk of identification of sensitive data of individual patients due to small subgroups;
722 therefore, the data are not openly accessible on request.

723

724

725

726 **Abbreviations**

727 BMI – body mass index; CAD – coronary artery disease; COPD – chronic obstructive pulmonary
728 disease; CRP – C-reactive protein; CMV – cytomegalovirus; CT – computer tomography; DBP –
729 low diastolic blood pressure; DD – D-dimer; Fbg – fibrinogen; GI disorders – gastrointestinal
730 disorders; HbA1c - glycohemoglobin A1c; LV - Left ventricular; 6MWT – six minute test; NT-
731 proBNP - ventricular natriuretic peptide; RBBB – right bundle branch block; SA – sinoatrial;
732 SBP – systolic blood pressure
733

734 **Legends to Tables**

735 **Table 1.** Clinical characteristic and comorbidities in participants after COVID-19 infection.

736 **Table 2.** Participants-reported clinical manifestations persistent after COVID-19 infection at
737 median of 6 months follow-up.

738 **Table 3.** Cardiac abnormalities detected in cardiac assessment of post-COVID-19 patients.

739 **Table 4.** Laboratory results of blood sample in participants after COVID-19 infection with
740 median follow-up of 6 months.

741

742 **Legends to the Figures**

743 **Figure 1.** Study flow diagram.

744 **Figure 2.** Clinical characteristics and laboratory results of blood samples in post-COVID-19
745 patients with and without type 2 diabetes: age, D-dimers (DD), ventricular natriuretic peptide
746 (NT-proBNP), C-reactive protein (CRP), body mass index (BMI), neutrophils, fasting glucose
747 and glycated hemoglobin (HbA1c) (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$).

748 **Figure 3.** Clinical characteristics and laboratory results of blood samples in post-COVID-19
749 patients with and without hypertension: age, BMI, NT-pro BNP, CRP, neutrophils, white blood

750 cells (WBC), DD, fasting glucose, HbA1c, HGB, fibrinogen and ferritin ($*p < 0.05$, $**p < 0.01$,
751 $****p < 0.0001$).

752 **Figure 4.** Clinical characteristics and laboratory results of blood samples in post-COVID-19
753 patients with no comorbidities (green), Hypertension only (blue), type 2 diabetes mellitus only
754 (orange) and both hypertension and type 2 diabetes mellitus (red): age, BMI, NT-proBNP, CRP,
755 neutrophils, WBC, DD, fasting glucose, HbA1c, HGB, fibrinogen and ferritin ($**p < 0.01$, $***p$
756 < 0.001 , $****p < 0.0001$).

757 **Figure 5.** Fibrotic changes in CT scan of post-COVID-19 patients with Hypertension (**A**).
758 Cardiac abnormalities in post-COVID-19 patients with and without hypertension (**B**); with and
759 without type 2 (**C**). ($*p < 0.05$, $***p < 0.001$, $****p < 0.0001$).

760

761 **Supplemental Data**

762 **Appendix 1.** Results of a questionnaire with items on demographic information, current
763 complaints, comorbidities, and medications.

764 **Appendix 2.** Results of a Chalder Fatigue Scale (CFS) questionnaire.

765 **Appendix 3.** CT abnormalities.